カテゴリ： GlobalData, 企業調査, 日本

Otsuka Pharmaceutical Co Ltd-製薬・医療分野：企業M&A・提携分析

◆英語タイトル：Otsuka Pharmaceutical Co Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA8014361
◆発行会社（調査会社）：GlobalData
◆発行日：2017年11月22日
◆ページ数：102
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：日本
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single UserUSD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Otsuka Pharmaceutical Co Ltd (OPC), a subsidiary of Otsuka Holdings Co Ltd is a provider of healthcare products. The company offers products which include pocari sweat, pocari sweat ion water, oronamin c, calorie mate, nature made, jerubure, jarinea, five mini, amino-value, enerugen, jog mate protein jelly, metro mint, the calcium, oronine and new sararin, among others. Its pharmaceutical products are used in the areas of central nervous system, cardiovascular, circulatory disease, infectious diseases, kidney, digestive disease, ophthalmology and dermatology. The company operates in the US, Japan, Belgium, Australia, the UK, Denmark, and others. OPC is headquartered in Tokyo, Japan.

Otsuka Pharmaceutical Co Ltd – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 6
Otsuka Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
Otsuka Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 8
Otsuka Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
Otsuka Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 10
Otsuka Pharmaceutical Co Ltd, Medical Devices Deals, 2011 to YTD 2017 11
Otsuka Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12
Otsuka Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deal Details 17
Partnerships 17
Ribomic Enters into Agreement with Seikagaku 17
Medibio Enters into Agreement with Otsuka Pharma 18
Ribomic Enters into Research Agreement with Astellas Pharma 19
Ribomic Enters into Research Agreement with Evec 20
Cambridge Isotope Laboratories Enters into Agreement with IROA Technologies 21
Otsuka Pharma Enters into Co-Development Agreement with NEC 22
RIKEN and Otsuka Pharma Forms Joint Venture 23
Earth Chemical to Enter into Agreement with Taiko Pharma 24
Astex Pharma Enters into Agreement with Genentech 25
Ariad Pharma Enters into Co-Marketing Agreement with Otsuka Pharma for Iclusig 26
Ribomic Extends Research Agreement with Otsuka Pharma 28
Probi Enters into Co-Marketing Agreement with Pharmavite 29
Horizon Discovery Enters into Development and Commercialization Agreement with Otsuka Pharma 30
Otsuka Enters Into Co-Promotion Agreement With Takeda For TAK-438 31
Lundbeck Enters Into Co-Development Agreement With Otsuka Pharma For Lu AF20513 32
Lundbeck Enters Into Co-Development Agreement With Otsuka Pharma 33
Avanir Pharma Enters Into Agreement With Merck To Promote Diabetes Drugs 34
Otsuka Pharma Enters Into Co-Promotion Agreement Lundbeck For Abilify 36
Otsuka Pharma Forms Joint Venture With Abdi Ibrahim To Market Otsuka’s Drugs In Turkey 37
Astex Pharma, Cancer Research Technology And Newcastle University Enter Into Drug Discovery Agreement 38
Astex Pharma, Cancer Research Technology And Institute of Cancer Research Enter Into Epigenetic Drug Discovery Agreement 40
Otsuka Pharma Amends Co-Development Agreement With UCB 42
Lundbeck Enters Into Co-Development Agreement With Otsuka Pharma 44
Proteros Biostructures Enters Into Drug Discovery Agreement With SuperGen 46
Licensing Agreements 47
Mylan Pharma Enters into Licensing Agreement with Otsuka Novel Products for Delamanid 47
R-Pharm Enters into Licensing Agreement with Otsuka Novel Products 48
Otsuka Pharma Enters into Licensing Agreement with Teva Pharma for TEV-48125 49
Otsuka Pharma to Enter into Licensing Agreement with Ribomic for RBM001 50
Otsuka Pharma Enters into Licensing Agreement with Akebia Therapeutics for Vadadustat 51
Otsuka Pharma Enters into Licensing Agreement with Akebia Therapeutics 53
Otsuka Pharma Enters into Licensing Agreement with Takara Bio 54
Medimetriks Pharma Enters into Licensing Agreement with Otsuka Pharma for OPA-15406 55
Fujimoto Pharma Enters into Licensing Agreement with Ribomic 56
Lundbeck Enters Into Licensing Agreement With Otsuka Pharma For Lu AE58054 57
Concert Pharma Enters Into Licensing Agreement With AVANIR Pharma For Neurology And Psychiatry Drugs 58
NuView Life Sciences Enters into Licensing Agreement with Otsuka Pharma for VPAC1 Biomarker 60
Otsuka Pharma Enters Into Licensing Agreement With Eisai 61
Avanir Pharma And OptiNose Enter Into Licensing Agreement For Treatment Of Acute Migraine 62
Proteus Biomedical Enters Into Licensing Agreement With Otsuka Pharma 64
Otsuka Pharma Enters Into Licensing Agreement With Kyowa Hakko Kirin For Saxagliptin 65
Equity Offering 66
Taiko Pharma to Raise Funds through Private Placement of Shares 66
Avanir Pharma Raises USD230 Million in Public Offering of Shares 67
Ribomic Raises USD26 Million in IPO of Shares 69
GlycoNex Announces Private Placement Of Shares For US$9.2 Million 70
Avanir Pharma Files Registration Statement For Public Offering Of Securities For Up To US$150 Million 71
Avanir Pharma Increases Size Of Private Placement Of Shares For US$80 Million 72
Astex Pharma Files Registration Statement For Public Offering Of Securities For US$200 Million 73
Asset Transactions 75
Tolero Pharma Acquires Drug Development Assets From Astex Pharma 75
Acquisition 77
Otsuka Pharma to Acquire Neurovance 77
Otsuka Acquires Avanir Pharma for USD3.5 Billion 78
Egypt Otsuka Pharmaceutical to Acquire 80% Stake in Ateco Pharma 80
Otsuka Pharma Completes Acquisition Of Astex Pharma For US$886 Million 81
Gimv Sells Stake In Astex Therapeutics 83
China Otsuka Pharmaceutical Acquires Dalian Taihua Pharmaceutical 84
SuperGen Completes Acquisition Of Astex Therapeutics 85
Otsuka Pharmaceutical Co Ltd – Key Competitors 88
Otsuka Pharmaceutical Co Ltd – Key Employees 89
Otsuka Pharmaceutical Co Ltd – Locations And Subsidiaries 90
Head Office 90
Other Locations & Subsidiaries 90
Joint Venture 95
Recent Developments 96
Government and Public Interest 96
Jun 06, 2016: GHIT Fund Welcomes Ten New Partnerships With FUJIFILM, Otsuka, GSK, Johnson & Johnson, Kyowa Hakko Kirin, Merck, Mitsubishi Tanabe, Nipro, Sumitomo Dainippon Pharma and Salesforce.com 96
Product News 98
May 09, 2016: Introducing Three New Flavors of Calorie Mate Jelly Focusing on the Need for a Nutritionally Balanced Jelly Beverage Option 98
01/07/2016: Neurovance Appoints Jeff Bailey to Chair Its Board of Directors 99
Clinical Trials 100
Jul 27, 2016: Neurovance Announces Positive Centanafadine Phase 2b Results for Adult ADHD, and Plans for Phase 3 Trials 100
Jan 07, 2016: Neurovance Announces Series of Three Clinical Trials to Support Advanced Development of Centanafadine (CTN) in Adult ADHD 101
Appendix 102
Methodology 102
About GlobalData 102
Contact Us 102
Disclaimer 102

List of Tables
Otsuka Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Key Facts 2
Otsuka Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
Otsuka Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 8
Otsuka Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
Otsuka Pharmaceutical Co Ltd, Deals By Therapy Area, 2011 to YTD 2017 10
Otsuka Pharmaceutical Co Ltd, Medical Devices Deals, 2011 to YTD 2017 11
Otsuka Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12
Ribomic Enters into Agreement with Seikagaku 17
Medibio Enters into Agreement with Otsuka Pharma 18
Ribomic Enters into Research Agreement with Astellas Pharma 19
Ribomic Enters into Research Agreement with Evec 20
Cambridge Isotope Laboratories Enters into Agreement with IROA Technologies 21
Otsuka Pharma Enters into Co-Development Agreement with NEC 22
RIKEN and Otsuka Pharma Forms Joint Venture 23
Earth Chemical to Enter into Agreement with Taiko Pharma 24
Astex Pharma Enters into Agreement with Genentech 25
Ariad Pharma Enters into Co-Marketing Agreement with Otsuka Pharma for Iclusig 26
Ribomic Extends Research Agreement with Otsuka Pharma 28
Probi Enters into Co-Marketing Agreement with Pharmavite 29
Horizon Discovery Enters into Development and Commercialization Agreement with Otsuka Pharma 30
Otsuka Enters Into Co-Promotion Agreement With Takeda For TAK-438 31
Lundbeck Enters Into Co-Development Agreement With Otsuka Pharma For Lu AF20513 32
Lundbeck Enters Into Co-Development Agreement With Otsuka Pharma 33
Avanir Pharma Enters Into Agreement With Merck To Promote Diabetes Drugs 34
Otsuka Pharma Enters Into Co-Promotion Agreement Lundbeck For Abilify 36
Otsuka Pharma Forms Joint Venture With Abdi Ibrahim To Market Otsuka’s Drugs In Turkey 37
Astex Pharma, Cancer Research Technology And Newcastle University Enter Into Drug Discovery Agreement 38
Astex Pharma, Cancer Research Technology And Institute of Cancer Research Enter Into Epigenetic Drug Discovery Agreement 40
Otsuka Pharma Amends Co-Development Agreement With UCB 42
Lundbeck Enters Into Co-Development Agreement With Otsuka Pharma 44
Proteros Biostructures Enters Into Drug Discovery Agreement With SuperGen 46
Mylan Pharma Enters into Licensing Agreement with Otsuka Novel Products for Delamanid 47
R-Pharm Enters into Licensing Agreement with Otsuka Novel Products 48
Otsuka Pharma Enters into Licensing Agreement with Teva Pharma for TEV-48125 49
Otsuka Pharma to Enter into Licensing Agreement with Ribomic for RBM001 50
Otsuka Pharma Enters into Licensing Agreement with Akebia Therapeutics for Vadadustat 51
Otsuka Pharma Enters into Licensing Agreement with Akebia Therapeutics 53
Otsuka Pharma Enters into Licensing Agreement with Takara Bio 54
Medimetriks Pharma Enters into Licensing Agreement with Otsuka Pharma for OPA-15406 55
Fujimoto Pharma Enters into Licensing Agreement with Ribomic 56
Lundbeck Enters Into Licensing Agreement With Otsuka Pharma For Lu AE58054 57
Concert Pharma Enters Into Licensing Agreement With AVANIR Pharma For Neurology And Psychiatry Drugs 58
NuView Life Sciences Enters into Licensing Agreement with Otsuka Pharma for VPAC1 Biomarker 60
Otsuka Pharma Enters Into Licensing Agreement With Eisai 61
Avanir Pharma And OptiNose Enter Into Licensing Agreement For Treatment Of Acute Migraine 62
Proteus Biomedical Enters Into Licensing Agreement With Otsuka Pharma 64
Otsuka Pharma Enters Into Licensing Agreement With Kyowa Hakko Kirin For Saxagliptin 65
Taiko Pharma to Raise Funds through Private Placement of Shares 66
Avanir Pharma Raises USD230 Million in Public Offering of Shares 67
Ribomic Raises USD26 Million in IPO of Shares 69
GlycoNex Announces Private Placement Of Shares For US$9.2 Million 70
Avanir Pharma Files Registration Statement For Public Offering Of Securities For Up To US$150 Million 71
Avanir Pharma Increases Size Of Private Placement Of Shares For US$80 Million 72
Astex Pharma Files Registration Statement For Public Offering Of Securities For US$200 Million 73
Tolero Pharma Acquires Drug Development Assets From Astex Pharma 75
Otsuka Pharma to Acquire Neurovance 77
Otsuka Acquires Avanir Pharma for USD3.5 Billion 78
Egypt Otsuka Pharmaceutical to Acquire 80% Stake in Ateco Pharma 80
Otsuka Pharma Completes Acquisition Of Astex Pharma For US$886 Million 81
Gimv Sells Stake In Astex Therapeutics 83
China Otsuka Pharmaceutical Acquires Dalian Taihua Pharmaceutical 84
SuperGen Completes Acquisition Of Astex Therapeutics 85
Otsuka Pharmaceutical Co Ltd, Key Competitors 88
Otsuka Pharmaceutical Co Ltd, Key Employees 89
Otsuka Pharmaceutical Co Ltd, Other Locations 90
Otsuka Pharmaceutical Co Ltd, Subsidiaries 90
Otsuka Pharmaceutical Co Ltd, Joint Venture 95

★海外企業調査レポート[Otsuka Pharmaceutical Co Ltd-製薬・医療分野：企業M&A・提携分析]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • U.S. HealthWorks Medical Group：企業のM&A・事業提携・投資動向
    U.S. HealthWorks Medical Group - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's U.S. HealthWorks Medical Group Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers a …
  • China State Shipbuilding Corp：企業の戦略・SWOT・財務情報
    China State Shipbuilding Corp - Strategy, SWOT and Corporate Finance Report Summary China State Shipbuilding Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Grifols SA (GRF)-製薬・医療分野：企業M&A・提携分析
    Summary Grifols SA (Grifols) focuses at improving the health and well-being of people around the world. It carries out the research, development, manufacturing and marketing of plasma-derived therapies, hospital pharmacy products and diagnostic technology for clinical use. The company specializes in …
  • Alabama Power Co：企業の戦略的SWOT分析
    Alabama Power Co - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …
  • Vindhya Telelinks Ltd：企業の戦略・SWOT・財務情報
    Vindhya Telelinks Ltd - Strategy, SWOT and Corporate Finance Report Summary Vindhya Telelinks Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Hindustan Unilever Limited：戦略・SWOT・企業財務分析
    Hindustan Unilever Limited - Strategy, SWOT and Corporate Finance Report Summary Hindustan Unilever Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Qisda Corporation
    Qisda Corporation - Strategy, SWOT and Corporate Finance Report Summary Qisda Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • PIQUR Therapeutics AG：製薬・医療：M&Aディール及び事業提携情報
    Summary PIQUR Therapeutics AG (PIQUR) is a developer of anti-cancer drugs. The company develops innovative small molecule therapeutics based on lipid kinase (PI3K) and mTOR inhibitior for the treatment of cancer and inflammatory diseases. Its pipeline products comprise PQR-309, PQR-620, PQR-530, PQR …
  • Owensboro Municipal Utilities：企業の戦略的SWOT分析
    Owensboro Municipal Utilities - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produ …
  • Leica Biosystems Nussloch GmbH：医療機器：M&Aディール及び事業提携情報
    Summary Leica Biosystems Nussloch Gmbh (Leica Biosystems) is a medical device company. The company provides histology and anatomical pathology workflow solutions. It offers histology equipment and consumables; immuo histochemistry, in situ hybridization, and fluorescence in situ hybridization (FISH) …
  • Dialog Semiconductor plc (DLG)-エネルギー分野：企業M&A・提携分析
    Summary Dialog Semiconductor plc (Dialog) is a supplier of motor control ICs for automotive applications. The company’s product portfolio includes integrated power management, AC/DC power conversion, solid state lighting (SSL), Bluetooth low energy, mixed signal integrated circuits (ICs), hand-held …
  • RIKEN：製薬・医療：M&Aディール及び事業提携情報
    Summary RIKEN is a research organization that carries out basic and applied science research programs. The organization’s research system consists of strategic research centers, research infrastructure centers, chief scientist system, etc. and a cluster for industry partnerships. Its centers, resear …
  • Cardiovascular Systems Inc (CSII)：企業の財務・戦略的SWOT分析
    Summary Cardiovascular Systems Inc (CSI) is a medical device company that develops and commercializes products for the treatment of peripheral and coronary vascular disease. The company's products include peripheral orbital atherectomy system, coronary orbital atherectomy system, crowns, and accesso …
  • Westside Corporation Pty Ltd：石油・ガス：M&Aディール及び事業提携情報
    Summary Westside Corporation Pty Ltd (Westside) is an oil and gas company that explores and produces coal seam gas. The company provides gas seam projects such as Paranui ATP 769P, Meridian SeamGas CSG fields, Tilbrook ATP 688P, and Mount Saint Martin ATP 688P, among others. It offers Paranui ATP 76 …
  • Mitsui Fudosan Co Ltd (8801)：企業の財務・戦略的SWOT分析
    Mitsui Fudosan Co Ltd (8801) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • 3M Co (MMM)：電力：M&Aディール及び事業提携情報
    Summary 3M Company (3M) is a diversified technology company that specializes in the development, manufacture and marketing of a wide range of innovative products. The company develops technology platforms, including adhesives, abrasives, light management, microreplication, non woven materials, nanot …
  • L’Oreal USA, Inc.：企業の戦略的SWOT分析
    L'Oreal USA, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • Pattern Energy Group Inc (PEGI)：企業の財務・戦略的SWOT分析
    Pattern Energy Group Inc (PEGI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Mesa Air Group, Inc.：企業の戦略・SWOT・財務情報
    Mesa Air Group, Inc. - Strategy, SWOT and Corporate Finance Report Summary Mesa Air Group, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Bunge Ltd (BG)：企業の財務・戦略的SWOT分析
    Bunge Ltd (BG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the po …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆